Grifols, S.A.

GRFS Healthcare Drug Manufacturers General

Grifols, S.A.’s revenue for fiscal 2025 (year ended December 2025) was $8.5 billion, up 9.07% from fiscal 2024. In the quarter to June 2026, revenue grew 5.76%, EPS grew 466.9%, free cash flow grew 300.5% and total debt was flat, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.

7.64 0.10 +1.33%
Market cap
$2.0B
P/E
8.5×
Fwd P/E
—
Dividend yield
1.24%
F-score
5/9
Altman Z
1.38
Beneish M
−2.59
Dividend safety
54/100
Dec '19 Jan '20 Dec '20 Jan '21 Dec '21 Jan '22 Dec '22 Dec '23 Dec '24 Dec '25
Piotroski F-Score
5 — 4 — 4 — 3 7 8 5
P/E ratio
20.33 20.60 17.64 18.13 19.76 20.49 24.97 55.25 20.88 10.35
Altman Z-Score
2.19 — 1.89 — 1.13 — 1.10 1.28 1.22 1.38
P/S ratio
2.92 2.96 2.04 2.10 0.39 0.40 0.24 0.00 0.75 0.75
Altman Z″-Score (non-manufacturers)
3.76 — 2.99 — 2.28 — 2.44 2.83 2.82 2.86
P/FCF ratio
39.35 39.87 20.66 21.23 5.73 5.94 272.22 0.00 18.29 9.85
Beneish M-Score
(2.32) — (2.43) — (2.53) — (2.08) (2.51) (2.49) (2.59)
P/Operating CF
61.09 61.90 38.06 39.11 9.50 9.85 (59.09) 0.00 16.66 13.70
Dividend Safety Score
— — — — — — — — — 54
P/B ratio
2.97 3.01 2.00 2.06 0.42 0.43 0.34 0.00 0.94 0.74
Price to Tangible BV
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EV/Sales
3.87 3.91 3.31 3.37 1.72 1.74 1.27 1.34 2.10 1.91
EV/EBITDA
14.66 14.81 13.39 13.62 9.24 9.32 7.98 7.94 10.44 8.51
EV/Operating CF
22.71 22.94 15.70 15.97 10.12 10.20 17.00 90.08 23.54 13.76
EV/FCF
52.13 52.66 33.44 34.01 25.33 25.54 1,462.80 (59.21) 51.23 25.24
Quick Ratio
2.14 0.81 0.78 0.33 0.91 0.67 0.65 0.60 0.93 0.80
Current Ratio
3.92 2.37 2.37 1.59 1.59 2.38 2.38 2.79 2.66 2.51
Net Debt/EBITDA
3.30 4.88 4.88 9.45 7.88 8.41 8.38 8.37 5.49 5.19
Debt/Assets
46.38% 45.25% 46.00% 48.28% 53.07% 45.01% 49.95% 51.57% 47.50% 48.92%
Debt/Equity
1.05 1.35 1.05 1.69 1.40 1.59 1.27 1.39 1.18 1.27
Asset Turnover
0.36 0.00 0.35 0.00 0.29 0.00 0.28 0.31 0.34 0.37
Operating CF/Net income
0.91 1.81 1.80 3.22 3.16 0.00 (0.05) 3.51 5.75 2.60
Capex/Depreciation
(1.35) 0.00 (1.13) 0.00 (0.19) 0.00 (0.91) (0.66) (0.79) (0.93)
Interest Coverage
3.30 243.75 3.99 94.17 2.14 40.35 1.62 1.34 1.67 1.99
ROE
10.60% 0.00% 9.21% 0.00% 2.73% 0.00% 2.50% 0.73% 1.89% 5.08%
ROA
4.36% 0.00% 4.05% 0.00% 1.11% 0.00% 0.97% 0.28% 0.73% 2.00%
ROIC
6.10% 0.00% 4.73% 0.00% 2.51% 0.00% 2.70% 2.72% 4.24% 4.74%
Return on Tangible Assets
10.16% 12.81% 14.89% 3.51% 4.12% 3.03% 3.49% 0.80% 2.27% 6.51%
Average Days of Receivables
32.38 34.45 31.14 36.63 36.05 45.44 41.04 39.87 39.63 36.48
Research and Development Expense of Revenue
5.41% 4.89% 5.51% 6.08% 7.19% 5.23% 5.96% 6.00% 5.32% 5.66%
Selling, General and Administrative Expense of Revenue
18.49% 16.76% 18.46% 19.40% 21.52% 18.09% 19.63% 20.73% 17.40% 15.72%
Intangible Assets out of Total Assets
0.45 0.45 0.45 0.41 0.41 0.46 0.46 0.45 0.48 0.49
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Graham Net Nets
(0.23) (0.23) (0.53) (0.51) (2.23) (2.15) (4.06) 0.00 (1.39) (1.25)
Graham Number
0.00 0.00 14.72 16.72 18.58 11.72 14.16 9.83 0.00 16.03
Earnings Yield
4.92% 4.86% 5.67% 5.52% 5.06% 4.88% 4.00% 1.81% 4.79% 9.66%
Free Cash Flow Yield
2.54% 2.51% 4.84% 4.71% 17.45% 16.83% 0.37% 0.00% 5.47% 10.15%
Revenue per Share
8.34 23.19 8.90 23.75 8.56 26.91 9.40 10.50 11.48 12.51
Operating CF per Share
0.93 4.86 1.85 2.93 1.04 0.00 (0.02) 0.33 1.44 1.74
Capex per Share
(0.67) 0.00 (0.60) 0.00 (0.12) 0.00 (0.58) (0.46) (0.55) (0.70)
Free Cash Flow per Share
0.26 4.86 1.25 2.93 0.92 0.00 (0.59) (0.13) 0.88 1.04
Cash per Share
4.04 2.52 0.98 3.15 4.66 2.43 0.92 1.07 1.95 1.43
Shareholders Equity per Share
11.19 22.18 11.20 26.59 12.70 27.20 13.11 12.69 13.70 12.64
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
11.19 22.18 11.20 26.59 12.70 27.20 13.11 12.69 13.70 12.64
Free Cash Flow
178.46 1,258.43 854.50 750.62 626.92 0.00 (403.68) (88.43) 599.81 710.52
Working Capital
4,475.10 2,056.18 2,090.20 2,513.58 2,408.75 3,065.91 2,842.34 4,476.72 3,864.61 3,456.43
Capital Expenditures
(458.75) (407.87) (413.84) (388.89) (79.36) (427.27) (392.23) (313.86) (376.42) (474.06)
Net Current Asset Value
(3,734.82) (6,037.08) (6,156.73) (7,987.65) (7,579.48) (9,698.86) (8,874.31) (7,594.13) (7,651.18) (7,959.40)
EV/EBIT
17.02 17.19 15.93 16.20 10.46 10.55 10.52 12.87 12.65 11.59
Capex to Sales
0.08 0.00 0.07 0.00 0.01 0.00 0.06 0.04 0.05 0.06
Price to Operating Income
12.85 13.02 9.84 10.11 2.37 2.45 1.96 0.00 4.51 4.52
Other line items
Depreciation/Fixed assets
0.14 0.11 0.14 0.11 0.14 0.10 0.12 0.14 0.13 0.14
Cash ROIC
0.96% 8.89% 5.22% 3.92% 2.62% 0.00% (1.93%) (0.41%) 2.77% 3.47%
Accounts Receivable Turnover
12.23 0.00 11.88 0.00 10.64 0.00 9.87 9.53 9.60 10.03
Accounts Payable Turnover
4.70 0.00 5.26 0.00 4.91 0.00 5.33 5.37 5.30 5.63
Inventory Turnover
1.25 0.00 1.44 0.00 1.42 0.00 1.34 1.25 1.26 1.39
Average Days of Payables
77.02 68.49 71.18 73.61 77.29 67.38 69.71 72.43 70.42 65.80
Days of Inventory on Hand
310.08 227.78 236.91 264.36 277.62 294.67 304.90 308.16 294.13 257.89
Average Receivables
466.81 536.44 513.50 565.77 548.45 717.22 647.45 748.86 813.30 849.05
Average Payables
657.65 664.06 669.47 731.89 715.69 787.99 757.65 825.59 901.16 936.89
Average Inventory
2,462.95 2,436.57 2,455.45 2,538.05 2,480.12 3,155.27 3,023.00 3,558.46 3,798.18 3,790.74
Average Assets
16,071.56 17,285.32 17,428.05 20,645.18 20,101.97 23,685.16 22,721.88 22,946.93 23,184.13 22,732.39
Average Common Equity
6,606.98 6,703.29 7,671.79 7,248.04 8,166.59 7,811.38 8,783.86 8,769.75 8,971.14 8,957.85

Fold the line items

Columns are period end dates